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INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is a malignancy which develops from lymphoid cell precursor (Lanzkowski 2011) . For several periods ALL therapy has developed succesful improvement with use chemotherapy agent as therapy (Christensen et al 2005) . Some protocols include steroid as an immunosupressant and in several studies show increased mortality and occurrence of infection because of the side effect from chemotherapy and high dose steroid therapy.
ALL patients have high mortality rate as a result of infection which occur because adrenal insufficiency in patients with high dose steroid therapy, so that in protocol it is recommended to tapering off the dose of steroid (Ansari et al 2014) . Besides, glucocortioid suppresses adrenal fuction and reduces immune system of the body against infection (Shulman et al 2007) . A study conduted by Conter et al (2009) showed the mortality in induction phase was about 1.6%. Another study by Prucker et al (2009) stated that 31 (3.4%) out of 396 patients died in induction phase and first complete remission. Another study showed 1.0%-1.3% average mortality in inducton phase (Pui 2000 , Christensen et al 2005 . Whereas, mean result of mortality in first complete remission is between 1.6%-3% (Silverman et al 2000 , Pui 2000 , Christensen et al 2005 , Conter et al 2009 , Prucker et al 2009 . In Indonesia, we did not find any study about the incident of adrenal suppression after high dose prednisone therapy, espescially during induction to consolidation phase in ALL patients.
The aim of this study was to analyze of changes in cortisol level as marker of adrenal suppression which happened in children with standard risk acute lymphoblastic leukemia in induction and consolidation phase after high dose prednisone therapy for long period.
MATERIALS AND METHODS
This was a longitudinal observational, prospective, nonrandomized trial study involving children with ALL who received prednisone for 49 days during the induction phase. We collected and compared the laboratory result of cortisol level in children with ALL and received prednisone therapy during induction to consolidation phase. We also collected data from the patients' medical record during the study period. Samples were taken for several weeks in the course of ALL chemotheraphy 2013 Indonesian protocol at Pediatric Department, Dr. Soetomo Hospital, Surabaya. In this study, we did not change or intervene the chemotherapy protocol used in Haematology Oncology Division Pediatric Department of Dr. Soetomo Hospital, Surabaya.
Blood samples were collected from all patients diagnosed with ALL standard risk and received prednisone therapy dose of 40 mg/m2/day for 49 days. Blood samples were taken in week 0, 4, 5, 6, 7, 8, 10, and 12 Descriptive analysis was performed to determine the demographic, patients' characteristics, and the profile of cortisol serum at weeks 0, 4, 5, 6, 7, 8, 10, 12 . Changes in cortisol level was measured by SPSS software using paired t-test methods. A p value <0.05 was regarded as significant.
RESULTS
There were 13 patients (8 males, 5 females) between June 2016 -January 2017. The demography and characteristic of the patients included in this study are shown in Table 1 . Mostly patients' age (76.9%) was 1-5 years and the number of male patients (61.5%) was higher than female patients (38.5%). The morphology result of BMP showed 8 patients (61.5%) belonged to LLA-L1 and 5 patients (38.5%) belonged to LLA-L2. 
DISCUSSION
Acute Lymphoblastic Leukemia (ALL) is a group of lymphoid disorders produced by monoclonal prolife-ration and expansion of immature lymphoid cells in the bone marrow, blood and other organs (Jabbour et al 2005 , Lanzkowsky 2011 . Other than that ALL is a malignancy mostly occur in children age 0-15 years (Ward et al 2014) .
Glucocorticoid mechanism that is used in the treatment of ALL was to induce apoptosis of leukemia cells. High dose prednisone therapy for 29 days required gradual dose reduction (tapering off). The aim of dose tapering is to prevent any secondary adrenal insufficiency (Pulungan et al 2010) . Prednisone has a role in modulating vascular response to maintain cardiac contractility, modulating vascular response to ß-adrenoceptor agonists and involved in the metabolism of glucose in the liver. When prednisone therapy is stopped without tapering off the dose, altered clinical symptoms may occur, such as hypotension and secondary adrenal insufficiency (tachycardia, decreased stroke volume, decreased peripheral vascular resistance) and hypoglycaemia (withdrawal syndrome) (Barthel et al 2015) .
Reduction of cortisol levels resulting from adrenal suppression provides high incidence of febrile neutropenia in patients receiving prednisone therapy that will increase the incidence of infection and increasing antibiotic therapy cost. From a study, incidence of infection was experienced by 8% of patients with acute or chronic adrenal suppression (Einaudi et al 2008) . Acute insufficiency is characterized by acute dehydration, hypotension, hypoglycemia, and impaired mental status, while the chronic insufficiency is characterized by anorexia, nausea, vomiting, loss of appetite, weight loss and depression (Shulman et al 2007) . In long term, adrenal suppression will inhibit growth in children (Ahmet et al 2011) .
CONCLUSION
Long-term high-dose prednisone therapy in standard risk LLA patients did not cause adrenal suppression until the week 6 of induction phase, the effect of decreased cortisol levels begun at weeks 7 and then recovered with a percentage decrease of 28% (mean cortisol levels was 27.52 µg/dL), a nadir in the week 10 consolidation phase with a percentage decrease of 51% (mean cortisol levels 17.92 µg/dL). Increased cortisol levels occurred in week 12 with percentage of increase 64% (mean cortisol levels was 29.31 µg/dL). At week 8 and week 10 each, there was one patient who experienced adrenal suppression.
